X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6967) 6967
Book Chapter (13) 13
Publication (5) 5
Conference Proceeding (4) 4
Dissertation (3) 3
Magazine Article (3) 3
Book / eBook (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
nivolumab (5957) 5957
oncology (3788) 3788
immunotherapy (3176) 3176
humans (3135) 3135
ipilimumab (2070) 2070
pembrolizumab (2060) 2060
cancer (1885) 1885
melanoma (1874) 1874
chemotherapy (1559) 1559
male (1472) 1472
docetaxel (1457) 1457
female (1396) 1396
open-label (1259) 1259
middle aged (1198) 1198
aged (1181) 1181
metastasis (1125) 1125
lung cancer (1079) 1079
patients (1046) 1046
survival (1015) 1015
tumors (963) 963
immunology (945) 945
care and treatment (902) 902
pd-1 (900) 900
safety (853) 853
immune checkpoint (804) 804
cancer therapies (788) 788
therapy (767) 767
adult (734) 734
blockade (726) 726
programmed cell death 1 receptor - antagonists & inhibitors (703) 703
apoptosis (692) 692
pd-l1 (692) 692
treatment outcome (663) 663
antibodies, monoclonal - therapeutic use (636) 636
multicenter (636) 636
clinical trials (634) 634
lymphocytes (628) 628
lung neoplasms - drug therapy (619) 619
antineoplastic agents, immunological - therapeutic use (614) 614
expression (591) 591
prognosis (591) 591
metastatic melanoma (582) 582
immune checkpoint inhibitors (565) 565
cell lung-cancer (559) 559
aged, 80 and over (532) 532
pd-1 blockade (531) 531
biomarkers (528) 528
analysis (522) 522
research (516) 516
immunotherapy - methods (510) 510
antineoplastic agents - therapeutic use (506) 506
pd-1 protein (504) 504
melanoma - drug therapy (500) 500
metastases (499) 499
advanced melanoma (494) 494
respiratory system (491) 491
antineoplastic agents, immunological - adverse effects (484) 484
mutation (475) 475
carcinoma, non-small-cell lung - drug therapy (470) 470
non-small cell lung cancer (462) 462
lung cancer, non-small cell (461) 461
adverse events (459) 459
nivolumab - therapeutic use (459) 459
medicine, research & experimental (434) 434
pd-l1 protein (425) 425
medical prognosis (422) 422
drug therapy (410) 410
cell death (399) 399
antibodies, monoclonal - adverse effects (391) 391
lung neoplasms - pathology (391) 391
ligands (389) 389
programmed cell death 1 receptor - immunology (388) 388
pharmacology & pharmacy (385) 385
neoplasms. tumors. oncology. including cancer and carcinogens (378) 378
atezolizumab (370) 370
lymphocytes t (361) 361
retrospective studies (361) 361
t-cells (361) 361
nivolumab - adverse effects (360) 360
medical research (359) 359
cytotoxicity (358) 358
immune checkpoint inhibitor (358) 358
immunohistochemistry (358) 358
antibody (355) 355
combined nivolumab (351) 351
anti-pd-1 (344) 344
checkpoint inhibitors (339) 339
efficacy (339) 339
case report (335) 335
review (335) 335
medicine & public health (333) 333
animals (332) 332
antigens (332) 332
non-small cell lung carcinoma (328) 328
b7-h1 antigen - antagonists & inhibitors (327) 327
antibodies, monoclonal, humanized - therapeutic use (325) 325
antibodies (323) 323
antineoplastic combined chemotherapy protocols - therapeutic use (323) 323
health aspects (321) 321
t cells (311) 311
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6709) 6709
French (98) 98
German (81) 81
Japanese (56) 56
Russian (26) 26
Korean (20) 20
Chinese (14) 14
Spanish (14) 14
Czech (5) 5
Italian (4) 4
Polish (2) 2
Portuguese (2) 2
Danish (1) 1
Dutch (1) 1
Hungarian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Oral oncology, ISSN 1368-8375, 2018, Volume 81, pp. 45 - 51
Journal Article
Cancer discovery, ISSN 2159-8290, 2018, Volume 8, Issue 7, pp. 822 - 835
Journal Article
Journal of cellular physiology, ISSN 0021-9541, 2018, Volume 233, Issue 10, pp. 6337 - 6343
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2019, Volume 381, Issue 21, pp. 2020 - 2031
Journal Article
Journal Article
BMC cancer, ISSN 1471-2407, 2019, Volume 19, Issue 1, pp. 1074 - 1074
Background Hypofractionated palliative radiotherapy for metastatic lung cancer patients is frequently used in order to ease pain, to increase bone stability,... 
Abscopal effect | PD-L1 EXPRESSION | Radioimmunotherapy | METASTASES | Palliative radiotherapy | DOCETAXEL | CHEMOTHERAPY | LOCAL RADIOTHERAPY | RADIATION-THERAPY | PEMBROLIZUMAB | ONCOLOGY | Immunotherapy | Nivolumab | Non-small cell lung cancer | RESISTANCE | PD-1 | IPILIMUMAB | Antineoplastic Agents, Immunological - administration & dosage | Carcinoma, Non-Small-Cell Lung - radiotherapy | Prospective Studies | Follow-Up Studies | Humans | Lung Neoplasms - radiotherapy | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Radiation Dose Hypofractionation | Response Evaluation Criteria in Solid Tumors | Biomarkers, Tumor - analysis | Nivolumab - therapeutic use | Lung Neoplasms - therapy | Nivolumab - adverse effects | Antineoplastic Agents, Immunological - pharmacology | Antineoplastic Agents, Immunological - adverse effects | Carcinoma, Non-Small-Cell Lung - therapy | Nivolumab - pharmacology | Antineoplastic Agents, Immunological - therapeutic use | Progression-Free Survival | Quality of Life | B7-H1 Antigen - analysis | Combined Modality Therapy - methods | Cohort Studies | Nivolumab - administration & dosage | Immune response | Analysis | Oncology, Experimental | Radiation | Lung cancer, Small cell | Respiratory agents | Metastasis | Research | Lung cancer, Non-small cell | Radiotherapy | Cancer | Index Medicus
Journal Article
Journal Article
BMC cancer, ISSN 1471-2407, 2019, Volume 19, Issue 1, pp. 974 - 10
Journal Article
Neurology, ISSN 1526-632X, 2018, Volume 91, Issue 14, pp. e1355 - e1359
OBJECTIVETo investigate the question of whether salvage therapy with the programmed cell death protein 1 (PD-1)–blocking antibodies nivolumab or pembrolizumab... 
GLIOBLASTOMA | 1ST | NIVOLUMAB | BEVACIZUMAB | CLINICAL NEUROLOGY
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2019, Volume 37, Issue 6, pp. 481 - 489
PURPOSE: Treatment options are limited for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Tumor cells can exploit the programmed... 
Hematopoietic Stem Cell Transplantation/adverse effects | Clinical Trial, Phase II | Humans | Middle Aged | Male | Journal Article | Research Support, N.I.H., Extramural | Young Adult | Time Factors | Treatment Failure | Aged, 80 and over | Adult | Female | Nivolumab/adverse effects | Chromosomes, Human, Pair 9 | Remission Induction | Disease Progression | Transplantation, Autologous/adverse effects | Lymphoma, Large B-Cell, Diffuse/drug therapy | Research Support, Non-U.S. Gov't | Progression-Free Survival | Multicenter Study | Aged | Programmed Cell Death 1 Receptor/antagonists & inhibitors | Antineoplastic Agents, Immunological/adverse effects | MULTICENTER | ONCOLOGY | PD-L1 | HODGKIN LYMPHOMA | OPEN-LABEL | OUTCOMES | DEATH LIGAND 1 | BLOCKADE | EXPRESSION | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Hematopoietic Stem Cell Transplantation - adverse effects | Lymphoma, Large B-Cell, Diffuse - immunology | Lymphoma, Large B-Cell, Diffuse - drug therapy | Lymphoma, Large B-Cell, Diffuse - surgery | Nivolumab - therapeutic use | Nivolumab - adverse effects | Antineoplastic Agents, Immunological - adverse effects | Antineoplastic Agents, Immunological - therapeutic use | Transplantation, Autologous - adverse effects | Programmed Cell Death 1 Receptor - immunology | Lymphoma, Large B-Cell, Diffuse - genetics | ORIGINAL REPORTS
Journal Article
BMJ, ISSN 1756-1833, 2018, Volume 363, p. k4226
Journal Article